<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682305</url>
  </required_header>
  <id_info>
    <org_study_id>TreoALL</org_study_id>
    <nct_id>NCT00682305</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation With Treosulfan, VP-16 and Cyclophosphamide for Patients With Acute Lymphoblastic Leukemia (ALL) Not Eligible for TBI-containing Conditioning Regimen: A Phase II-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a multicenter, prospective phase II-study investigating the combination
      of treosulfan, etoposide, and cyclophosphamide as conditioning regimen for patients with
      acute lymphoblastic leukemia who are not eligible for a TBI-containing regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of engraftment at day +28 and non-relapse mortality at day +100 and at 1 year after SCT</measure>
    <time_frame>1 year after SCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>*Incidence of aGvHD on day +100/ cGvHD at 1 and 2 yrs after SCT/ relapse at 2 yrs after SCT *Toxicity *Disease-free survival at 2 yrs after SCT *overall survival at 2 yrs. after SCT</measure>
    <time_frame>2 years after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <description>conditioning regimen:
day -7: 12g/m^2 Treosulfan
day -6: 12g/m^2 Treosulfan
day -5: 12g/m^2 Treosulfan
day -4: 30mg/kg BW Etoposide
day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide
day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide
day -1: 20mg/kg ATG Fresenius (OPTIONAL)
day 0: SCT</description>
    <arm_group_label>Single-Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute lymphoblastic leukemia in first or subsequent complete remission

          -  Indication for allogeneic stem cell transplantation according to the actual protocol
             of the German Acute Lymphoblastic Leukemia Study Group

          -  Patient's age: 18-65 years

          -  HLA-identical or compatible related or unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DRB1
             and HLA-DQB1) (one antigen-mismatch allowed)

          -  Not eligible for total-body irradiation due to one of the following reasons:

               -  prior radiation of the spine &gt; 30 Gy

               -  prior radiation of the mediastinum &gt; 30 Gy

               -  severe pulmonary infection during induction chemotherapy

               -  DLCO &gt; 50%

          -  Patient's wishing to avoid total-body irradiation as conditioning regimen

          -  Patient's written informed consent

          -  Women and men capable of reproduction must agree to use highly effective methods of
             contraception until six months after treatment termination. For men: vasectomy, sexual
             abstinence, or partner is using hormonal IUD, implants, injectables, oral hormonal
             contraceptives or is surgically sterilized. For women: hormonal IUD, implants,
             injectables, sexual abstinence, surgical sterilization, vasectomised partner

        Exclusion Criteria:

          -  No complete remission at time of registration

          -  Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as

               -  total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level

               -  Left ventricular ejection fraction &lt; 30%

               -  Creatinine clearance &lt; 30 ml/min

               -  DLCO &lt; 35% and/ or receiving supplementary continuous oxygen

          -  Positive serology HIV

          -  Pregnant or lactating women

          -  Severe florid infection

          -  Experienced hypersensitivity against cyclophosphamid, etoposide, or treosulfan

          -  Cystitis

          -  Obstructive renal function

          -  Participation in any other clinical drug trial

          -  Serious psychiatric or psychological disorders

          -  Progressive invasive fungal infection at time of registration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Department for Stem Cell Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Hematopoeitic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

